Publication | Open Access

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

Chronic PhaseHematological MalignancyOncologyMedicineMalignant Blood DisorderHematologyExposure-response AnalysisPharmacotherapyPharmacologyMyeloid Neoplasia